bioRxivCancer Biology
Limited inhibition of multiple nodes in a driver network blocks metastasis
A. E. Yesilkanal, D. Yang, P. Tiwari, A. U. Sabino, J. Lee, X.-H. Xie, S. Sun, C. Dann, E. Steinberg, T. Stuhlmiller, C. Frankenberger, E. Goldsmith, G. L. Johnson, A. F. Ramos, M. R. Rosner
Abstract
Metastasis suppression by high-dose, multi-drug targeting is largely unsuccessful due to network heterogeneity and compensatory network activation. Here we show that targeting driver network signaling capacity by limited inhibition of its core pathways is a more effective anti-metastatic strategy. This principle underlies the action of a physiological metastasis suppressor, Raf Kinase Inhibitory Protein, which moderately decreases stress-regulated MAP kinase network activity, reducing the output to metastatic transcription factor BACH1 and motility-related target genes. We developed a low-dose four-drug mimic that blocks metastatic colonization in mouse breast cancer models and increases survival. Experiments and network flow modeling show: 1) limited inhibition of multiple pathways is required to overcome variation in MAPK network topology and suppress signaling output across heterogeneous tumor cells, and 2) restricting inhibition of individual kinases dissipates surplus signal, preventing threshold activation of compensatory kinase networks. This low-dose multi-drug approach to decrease signaling capacity of driver networks represents a transformative, clinically-relevant strategy for anti-metastatic treatment.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Multiple cancer types rapidly escape from multiple MAPK inhibitors to generate mutagenesis-prone subpopulations
T. E. Hoffman, C. Yang, … S. L. Spencer·bioRxiv·Mar 17, 2023
- Oncogenic RAS-MET signal interactions are modulated by P53 status in NF1-related MPNSTs
Matthew G. Pridgeon, Elizabeth A. Tovar, … Matthew R. Steensma·bioRxiv·Oct 5, 2017
- Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanoma
Helma Zecena, Daniel Myklatun Tveit, … Fabian V. Filipp·BMC Systems BiologyPeer-reviewed·Apr 3, 2018
- Spatial modulation of RAF by RAF/MEK glue enables full-dose combination with pan-RAF inhibitor and potent RAS-mutant tumor-selective MAPK and growth inhibition
Ana Orive-Ramos, Bijaya Gaire, … Poulikos I. Poulikakos·Cancer DiscoveryPeer-reviewed·Sep 29, 2026
- Capitalizing on paradoxical activation of the MAPK pathway for treatment of Imatinib-resistant mast cell leukemia and chronic myelogenous leukemia
T. Wilhelm, M. A. Toledo, … M. Huber·Hematological OncologyPeer-reviewed·Nov 30, 2022
- A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway inhibition
Jesse D. Riordan, Teagan A. Nathanson, … Christopher S. Stipp·OncogenePeer-reviewed·Oct 18, 2025